Is the Market Going to Go Lower?
The last month has been extremely difficult for the stock…
Sell
45
PTCT Quote, Financials, Valuation and Earnings
Last price:
$57.15
Seasonality move
:
1.27%
Day range:
$53.09 - $55.65
52-week range:
$24.00 - $55.65
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
5.19x
P/B ratio:
--
Volume:
861.9K
Avg. volume:
860.1K
1-year change:
88.65%
Market cap:
$4.3B
Revenue:
$806.8M
EPS (TTM):
-$4.73
Analysts' Opinion
-
Consensus RatingPTC Therapeutics has received a consensus rating of Buy. The company's average rating is a Buy based on 6 Buy ratings, 4 Hold ratings, and 1 Sell rating.
-
Price Target UpsideAccording to analysts' consensus price target of $64.93, PTC Therapeutics has an estimated upside of 19.14% from its current price of $54.50.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $42.00 representing 22.94% downside risk from its current price of $54.50.
Fair Value
-
According to the consensus of 11 analysts, PTC Therapeutics has 19.14% upside to fair value with a price target of $64.93 per share.
PTCT vs. S&P 500
-
Over the past 5 trading days, PTC Therapeutics has overperformed the S&P 500 by 6.04% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
PTC Therapeutics does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
PTC Therapeutics revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter PTC Therapeutics reported revenues of $213.2M.
Earnings Growth
-
PTC Therapeutics has grown year-over-year earnings for 0 quarters straight. In the most recent quarter PTC Therapeutics reported earnings per share of -$0.85.
Enterprise value:
5.5B
EV / Invested capital:
4.35x
Price / LTM sales:
5.19x
EV / EBIT:
--
EV / Revenue:
6.85x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-30.37x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$749.4M
Return On Assets:
-19.86%
Net Income Margin (TTM):
-45.03%
Return On Equity:
--
Return On Invested Capital:
-382.54%
Operating Margin:
-7.45%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $698.8M | $937.8M | $806.8M | $307.1M | $213.2M | |
| Gross Profit | $654.1M | $872.3M | $749.4M | $277.9M | $196.9M | |
| Operating Income | -$439.9M | -$349.4M | -$146.7M | $3.1M | -$15.9M | |
| EBITDA | -$367.8M | -$330.3M | -$120.5M | -$32.1M | -$46.9M | |
| Diluted EPS | -$7.79 | -$8.36 | -$4.73 | -$2.06 | -$0.85 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $1.2B | $954.4M | $693.8M | $1.2B | $1.4B | |
| Total Assets | $2.2B | $1.9B | $1.7B | $1.9B | $1.7B | |
| Current Liabilities | $277.3M | $509.3M | $406.2M | $603.1M | $581M | |
| Total Liabilities | $1.7B | $1.9B | $2.1B | $2.7B | $2.8B | |
| Total Equity | $482M | $1.4M | -$347.1M | -$818.6M | -$1.1B | |
| Total Debt | $309.1M | $1.2B | $1.3B | $2.1B | $2.4B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$356.7M | -$158.4M | -$107.7M | -$100.3M | -$30M | |
| Cash From Investing | $290.2M | -$176.7M | $44.2M | -$94.4M | $267.7M | |
| Cash From Financing | $168M | $646.4M | $255.9M | $620.5M | $26.5M | |
| Free Cash Flow | -$509.1M | -$279M | -$181.9M | -$128.8M | -$36.5M | |
PTCT
Sector
Market Cap
$4.3B
$37.4M
Price % of 52-Week High
97.93%
45.61%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.75%
1-Year Price Total Return
88.65%
-38.36%
Beta (5-Year)
0.660
0.774
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Buy
Level
$52.82
200-day SMA
Buy
Level
$40.33
Bollinger Bands (100)
Buy
Level
41.86 - 50.26
Chaikin Money Flow
Buy
Level
19.6M
20-day SMA
Buy
Level
$51.70
Relative Strength Index (RSI14)
Buy
Level
63.40
ADX Line
Buy
Level
21.64
Williams %R
Sell
Level
-10.1411
50-day SMA
Buy
Level
$48.31
MACD (12, 26)
Buy
Level
1.46
25-day Aroon Oscillator
Buy
Level
40
On Balance Volume
Neutral
Level
62.7M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-1.5979)
Sell
CA Score
(Annual)
Level (-5.5202)
Buy
Beneish M-Score
(Annual)
Level (-3.3947)
Buy
Momentum Score
Level (10)
Sell
Ohlson Score
Level (7.7646)
Buy
Piotroski F Score
(Annual)
Level (4)
Buy
Quality Ratio Score
Level (5)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The Company views its operations and manages its business in one operating segment: life science.
Stock Forecast FAQ
In the current month, PTCT has received 6 Buy ratings 4 Hold ratings, and 1 Sell ratings. The PTCT average analyst price target in the past 3 months is $64.93.
-
Where Will PTC Therapeutics Stock Be In 1 Year?
According to analysts, the consensus estimate is that PTC Therapeutics share price will rise to $64.93 per share over the next 12 months.
-
What Do Analysts Say About PTC Therapeutics?
Analysts are divided on their view about PTC Therapeutics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that PTC Therapeutics is a Sell and believe this share price will drop from its current level to $42.00.
-
What Is PTC Therapeutics's Price Target?
The price target for PTC Therapeutics over the next 1-year time period is forecast to be $64.93 according to 11 Wall Street analysts, 6 of them rate the stock a Buy, 1 rates the stock a Sell, and 4 analysts rate the stock a Hold.
-
Is PTCT A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for PTC Therapeutics is a Buy. 6 of 11 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of PTCT?
You can purchase shares of PTC Therapeutics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase PTC Therapeutics shares.
-
What Is The PTC Therapeutics Share Price Today?
PTC Therapeutics was last trading at $57.15 per share. This represents the most recent stock quote for PTC Therapeutics. Yesterday, PTC Therapeutics closed at $54.50 per share.
-
How To Buy PTC Therapeutics Stock Online?
In order to purchase PTC Therapeutics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
2 Dividend Stocks to Buy in a Recession
While many economists and investors initially expected 2025 to be…
Is Ford Stock Undervalued Amid the EV Transition?
There is a lot going on in the electric vehicle…
Stock Ideas
Buy
52
Is AAPL Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 35x
Buy
56
Is NVDA Stock a Buy?
Market Cap: $3T
P/E Ratio: 41x
Buy
53
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Alerts
Sell
49
SMTC alert for Mar 17
Semtech [SMTC] is down 0.49% over the past day.
Buy
62
PLPC alert for Mar 17
Preformed Line Products [PLPC] is up 3.8% over the past day.
Sell
50
NUTX alert for Mar 17
Nutex Health [NUTX] is up 4.82% over the past day.
